TAYSHA GENE THERAPIES INC

NASDAQ: TSHA (Taysha Gene Therapies, Inc.)

Kemas kini terakhir: 22 jam lalu

4.10

-0.11 (-2.61%)

Penutupan Terdahulu 4.21
Jumlah Dagangan 2,474,566
Harga / Jualan (P/S) 280.23
Harga / Buku (P/B) 3.74
Julat 52 Minggu
3.46 (-15%) — 7.30 (78%)
Margin Operasi (TTM) -930.54%
EPS Cair (TTM) -0.340
Pertumbuhan Hasil Suku Tahunan (YOY) -32.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 111.93%
Nisbah Semasa (MRQ) 5.35
Aliran Tunai Operasi (OCF TTM) -83.45 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -52.28 M
Pulangan Atas Aset (ROA TTM) -35.91%
Pulangan Atas Ekuiti (ROE TTM) -159.34%

AISkor Stockmoo

-0.5
Nilai 30% -1.4
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Pulangan atas Modal info NA
Masa 30% -2.4
Daripada analisis teknikal AI kami terhadap carta. info NA
Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Corak Lilin info NA
Aliran bagi Tempoh Pegangan Anda info NA
Sentimen 20% 0.0
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Sentimen Berita info NA
Wang Pintar 20% 3.2
Aktiviti Orang Dalam info NA
Institusi bersih +10.38% daripada saham dalam pemfailan 13F terkini: 137 pemegang menambah, 74 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat +14.3% dari 31 Aug hingga 30 Oct 2026, 14.8 hari untuk tutup (FINRA). info
Keadaan pasaran dan sektor lemah.
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak tidak sependapat, jadi skor dilemahkan.
Tidak dikira dalam skor
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Momentum jangka pendek meningkat. info
Harga hampir dengan paras sokongan. Paras sokongan dan rintangan menurun. info
Skor Akhir -0.49

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Taysha Gene Therapies, Inc. Bercampur Menaik

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
TSHA - - - 3.74
VRNA 9 B - - 33.01
OPT 583 M - - 4.31
VRCA - - - 15.60
ABEO - - - 1.04
VKTX - - - 6.33

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 12.11%
% Dimiliki oleh Institusi 67.23%

Pemilikan

Nama Tarikh Syer Dipegang
Polar Capital Holdings Plc 30 Jun 2026 5,117,133

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 97.20%

Kedudukan Pemegang Saham
Bertambah 137 37,295,049
Berkurang 74 15,115,926
Baharu 43 16,801,077
Dijual habis 22 5,137,834

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 53,478,497 14.8
15 Oct 2026 51,249,292 11.6
30 Sep 2026 55,020,663 11.2
15 Sep 2026 51,405,384 18.8
31 Aug 2026 46,800,424 19.4
14 Aug 2026 46,738,149 17.4

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

0 Positif 0 Negatif 5 Neutral
Tarikh Jenis Butiran
13 Nov 2026 Yahoo Finance Taysha (TSHA) Q3 2026 Earnings Call Transcript
Management says 33 patients dosed so far with no severe treatment-related events.
12 Nov 2026 Yahoo Finance Taysha Gene Therapies Q3 Earnings Call Highlights
Taysha Gene Therapies (NASDAQ:TSHA) expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing pathway in the first half of 2027, executives said on the company’s third-quarter earnings call. The comp…
12 Nov 2026 Yahoo Finance Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across…
06 Nov 2026 Yahoo Finance Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today…
05 Nov 2026 Yahoo Finance Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today…
30 Oct 2026 Yahoo Finance Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book Value
Taysha Gene Therapies has seen sharp swings in its share price over recent years, and that volatility puts a spotlight on a basic question for holders: Is the market value you see on screen today in line with what its balance sheet and book value can reasonably support? Over the past 3 years the…
18 Oct 2026 Yahoo Finance Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies reported phase 1/2 REVEAL data in Rett syndrome, where all 10 participants receiving a single intrathecal TSHA-102 dose gained or regained at least one developmental milestone and no treatment-related serious adverse events were observed. These findings support the therapy's…
09 Oct 2026 Yahoo Finance Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
Taysha Gene Therapies has delivered a 90.1% gain over the past three years, which puts fresh attention on whether that kind of move is backed up by the value on its balance sheet. With the share price at US$4.43 at the last close, the live question is how comfortably that level sits against the…
09 Oct 2026 Yahoo Finance Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
Taysha Gene Therapies (TSHA) has drawn fresh attention after a period of pressure on the share price, with the stock roughly flat over the past day but lower over the past month and the past three months. Short term momentum for Taysha Gene Therapies has clearly cooled, with the 7 day share price…
01 Oct 2026 Yahoo Finance Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today…
07 Sep 2026 Yahoo Finance These 3 Risky Stocks Could Be Sitting on 100% Upside
Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks.
18 Aug 2026 Yahoo Finance Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
TSHA-102 dosing complete in pivotal Rett syndrome trials with 100% responder rate.
Papar semua

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda